What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study.

Roldan Munoz, Sonia; Postmus, Douwe; de Vries, Sieta T; Gross-Martirosyan, Liana; Bahri, Priya; Hillege, Hans; Mol, Peter G M

Roldan Munoz, Sonia; Postmus, Douwe; de Vries, Sieta T; Gross-Martirosyan, Liana; Bahri, Priya; Hillege, Hans; Mol, Peter G M.

Affiliation

Roldan Munoz S; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Postmus D; Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
de Vries ST; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Gross-Martirosyan L; Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
Bahri P; Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
Hillege H; European Medicines Agency, Amsterdam, The Netherlands.
Mol PGM; Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Drug Saf ; 46(3): 243-255, 2023 03.

Article in En | MEDLINE | ID: mdl-36790560

Subject(s)

Sodium-Glucose Transporter 2 Inhibitors; Adult; Female; Humans; Male; Middle Aged; Cross-Sectional Studies; Pharmacovigilance; Surveys and Questionnaires

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sodium-Glucose Transporter 2 Inhibitors Type of study: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Drug Saf Journal subject: TERAPIA POR MEDICAMENTOS / TOXICOLOGIA Year: 2023 Document type: Article Affiliation country: Netherlands Country of publication: New Zealand

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google